Hygea Medical is striving to build a world-leading interventional oncology integrated platform
Hygea Medical (Chinese: 海杰亚医疗) announced that it had completed a CNY 100 million Series D funding round, which was led by In Capital (Chinese: 约印医疗基金) and followed by Banyan Pacific Capital (Chinese: 榕泉资本), HuaJin Capital (Chinese: 华金资本), Unifortune (Chinese: 乾道基金), and MeiHong Fund (Chinese: 美鸿基金). The long-term backer Gaorong Capital (Chinese: 高榕资本) continued to invest. HaoYue Capital (Chinese: 浩悦资本) acted as the exclusive financial adviser.
Proceeds raised in this round will be used to further strengthen business expansion and channel construction, expand R&D pipelines, strengthen the product portfolio in cancer treatment, and accelerate the international strategy.
Founded in 2010, Hygea Medical is a National High-tech Enterprise integrating R&D, production, sales and marketing, focusing on interventional oncology fields of "percutaneous intervention" and "transvascular intervention". The company has set up Beijing Key Laboratory of Cryogenic Biomedical Engineering and Post-Doctoral Research Center. As to patents, the company obtains more than 150 patents both in China and abroad. Relying on its innovation and expertise, it was granted awards of the William Begell Medal, National Specialized and New "Little Giant" Enterprise, First Prize of Beijing Science and Technology Award, etc.
The first released product, "Co-Ablation System", is the new generation minimally invasive tumor treatment system. It introduces the first combined ablation system in the world by integrating cryoablation and hyperthermia ablation in one system. In 2020, Co-Ablation System obtained the CE Marking Certificate and started product marketing in European countries. In 2021, it was included in healthcare insurance.
Hygea Medical's competitors include Etters Medical (Chinese: 百德医疗), SensCure Biotech (Chinese: 胜杰康), and Eco (Chinese:亿高医疗).